OncoMatch/Clinical Trials/NCT06562166
Online Adaptive Radiotherapy for Cervical Cancer
Is NCT06562166 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for cervical cancer.
This study aims to evaluate the clinical efficacy and safety of online adaptive radiotherapy for cervical cancer patients received radical radiotherapy. By comparing with image-guided radiotherapy, the study explores the potential advantages of online adaptive radiotherapy in reducing treatment toxicity and improving local control.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage II, IIIB, IIIC1
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiotherapy
Have received radiotherapy in the past
Cannot have received: chemotherapy
Have received chemotherapy in the past
Cannot have received: surgery
Have undergone radical surgery for cervical cancer
Lab requirements
Blood counts
NEUT ≥ 1.5*10^9/L, HGB ≥ 60g/L, platelets ≥ 100×10^9/L
Kidney function
blood creatinine <1.5 mg/dL
Liver function
AST and ALT are within 2 times the upper limit of normal
Complete blood count and basal metabolic indexes within 14 days before enrolment must meet the following requirements: NEUT ≥ 1.5*109/L, HGB ≥ 60g/L, platelets ≥ 100×109/, blood creatinine <1.5 mg/dL. AST and ALT are within 2 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify